Literature DB >> 3454797

Association of HLA-DRw9 with myasthenia gravis in Chinese.

H C Chiu1, R P Hsieh, K H Hsieh, T P Hung.   

Abstract

HLA phenotypes were studied in 59 Chinese myasthenia gravis (MG) patients. Unfractionated peripheral blood mononuclear cells were used for typing of HLA-A, B and C, and B-enriched lymphocytes for HLA-DR. Seventy-nine healthy subjects were included as controls. When compared with healthy controls, the patients showed significant increases in HLA-Bw46 (47.5% versus 14%, chi 2 = 18.7, P less than 0.001), HLA-DRw9 (59.3% versus 11%, chi 2 = 35.7, P less than 0.001), while HLA-DR3 was decreased (3.4% versus 32.9%, chi 2 = 18.2, P less than 0.001). Further analysis showed that the primary association was with DRw9 and the increase in Bw46 was secondary to it. Both HLA-Bw46 and -DRw9 were increased in all subgroups except where the age of onset was greater than 40 years. Finally, the HLA-A2-Bw46-DRw9 combination was also significantly increased in patients (25.4% versus 5.1%, chi 2 = 11.5, P less than 0.001), especially in the subgroups of MG with age of onset of less than 10 and males with age of onset of less than 40 years.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3454797     DOI: 10.1111/j.1744-313x.1987.tb00382.x

Source DB:  PubMed          Journal:  J Immunogenet        ISSN: 0305-1811


  3 in total

1.  Immunoglobulin heavy chain gene associations in myasthenia gravis: new evidence for disease heterogeneity.

Authors:  A Demaine; N Willcox; M Janer; K Welsh; J Newsom-Davis
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

2.  Linkage disequilibrium study of RFLPs detected at the human muscle nicotinic acetylcholine receptor subunit genes.

Authors:  E A Lobos; C H Rudnick; M S Watson; K E Isenberg
Journal:  Am J Hum Genet       Date:  1989-04       Impact factor: 11.025

3.  Association of HLA-Bw46DR9 combination with juvenile myasthenia gravis in Chinese.

Authors:  W H Chen; H C Chiu; R P Hseih
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.